USFDA concludes inspection at Glenmark Pharmaceuticals’ Baddi facility with six observations

23 Jun 2022 Evaluate

The United States Food and Drug Administration (USFDA) has concluded an inspection at Glenmark Pharmaceuticals’ formulation manufacturing facility-- Baddi, India. The inspection commenced on June 13, 2022 and concluded on June 22, 2022. USFDA has issued Form 483 with six observations after an inspection.

The Company is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1690.95 -2.35 (-0.14%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.